Sugi Predict

Sugi Predict / Targets / GGH

GGH

Gamma-glutamyl hydrolase · Q92820 · GGH on Sugi Atlas →

1,751 patent compounds predicted against GGH, 1,250 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL1374837 SCHEMBL1374837 1.00 2/20
SCHEMBL1374839 SCHEMBL1374839 1.00 2/20
SCHEMBL1377570 SCHEMBL1377570 1.00 2/20
SCHEMBL1377572 SCHEMBL1377572 1.00 2/20
SCHEMBL5054338 SCHEMBL5054338 0.80 2/20
SCHEMBL5054466 SCHEMBL5054466 0.77 2/20
SCHEMBL5060461 SCHEMBL5060461 0.76 2/20
SCHEMBL7606155 SCHEMBL7606155 0.76 2/20
SCHEMBL5053165 SCHEMBL5053165 0.75 2/20
SCHEMBL5053167 SCHEMBL5053167 0.75 2/20
SCHEMBL5053238 SCHEMBL5053238 0.75 2/20
SCHEMBL5051352 SCHEMBL5051352 0.73 2/20
SCHEMBL7605221 SCHEMBL7605221 0.73 2/20
SCHEMBL1615009 SCHEMBL1615009 0.72 2/20
SCHEMBL5051207 SCHEMBL5051207 0.72 2/20
SCHEMBL2368106 SCHEMBL2368106 0.71 2/20
SCHEMBL2368111 SCHEMBL2368111 0.71 2/20
SCHEMBL2368891 SCHEMBL2368891 0.71 2/20
SCHEMBL1376216 SCHEMBL1376216 0.69 2/20
SCHEMBL1376219 SCHEMBL1376219 0.69 2/20

Clinical trials — most relevant to GGH by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Efficacy and Safety of Intrathecal OAV101 (AVXS-101) in Pediatric Patients With Type 2 Spinal Muscular Atrophy (SMA) PHASE3COMPLETED
Study to Evaluate the Diagnostic Performance of GEH300079 (68Ga) Injection PET/CT for Detection of PC in Patients With Colorectal, Gastric, Ovarian, or Pancreatic Cancers (PERISCOPE) PHASE2/PHASE3RECRUITING
Compare Efficacy, Safety and Immunogenicity of HLX02 and Herceptin in Previously Untreated HER2 +Overexpressing Metastatic Breast Cancer PHASE3COMPLETED
Phase 3b Study to Evaluate Skeletal Response to Eliglustat in Adult Patients Who Completed Phase 2 or Phase 3 Studies PHASE3COMPLETED
SGM-101 in Locally Advanced and Recurrent Rectal Cancer PHASE2/PHASE3UNKNOWN
A Single-blind Pilot Study to Investigate Safety and Tolerability of the Chymase Inhibitor BAY1142524 in Clinically Stable Patients With Left-ventricular Dysfunction PHASE2COMPLETED
First-in-human Study of UX016 in GNEM PHASE1/PHASE2NOT_YET_RECRUITING
A Phase II Open-label Single-arm Study to Evaluate the Efficacy and Safety of ADSCs in Subjects With Liver Cirrhosis PHASE2UNKNOWN
TCHP Versus EC -THP as Neoadjuvant Treatment for HER2-Positive Breast Cancer PHASE2UNKNOWN
Histone Deacetylase Inhibitor LBH589 in Addition to Corticosteroids in Patients With Acute Graft Versus Host Disease (GVHD) PHASE1/PHASE2COMPLETED
A Study to Investigate the Virologic Efficacy and Safety of VH3810109 + Cabotegravir Compared to Standard of Care (SOC) in Male and Female Adults Living With Human Immunodeficiency Virus (HIV) PHASE2ACTIVE_NOT_RECRUITING
Ofatumumab Induction and Maintenance in Elderly Patients With Poor Risk CLL in the Context of Allogeneic Transplantation PHASE2COMPLETED
GLPG2737 on Top of Orkambi in Subjects With Cystic Fibrosis PHASE2COMPLETED
A Study of SGN-35 (Brentuximab Vedotin) of Patients With Relapsed or Refractory PMLBCL PHASE2COMPLETED
An Efficacy and Safety Study of Mongersen (GED-0301) in Subjects With Active Ulcerative Colitis PHASE2COMPLETED
A Study of MCARH109 and MCARH125 in People With Multiple Myeloma PHASE1ACTIVE_NOT_RECRUITING
A Phase I, Two-part Study to Determine the Recommended Dose and Evaluate the Safety and Tolerability of a Novel Oral Arsenic Trioxide Formulation (ORH-2014) in Subjects With Advanced Hematological Disorders PHASE1COMPLETED
A Study of RGLS4326 in Patients With Autosomal Dominant Polycystic Kidney Disease PHASE1COMPLETED
MCARH109 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of Multiple Myeloma PHASE1ACTIVE_NOT_RECRUITING
Investigating Mechanism of Action of DAC HYP in the Treatment of High-Inflammatory Multiple Sclerosis (MS) PHASE1COMPLETED
A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Repeat Doses of RV1729 for 28 Days in Patients With COPD PHASE1COMPLETED
A Study to Test How Well Different Doses of BI 3034701 Are Tolerated by Healthy Men and People With Overweight or Obesity PHASE1COMPLETED
A Study to Evaluate YH003 in Subjects With Advanced Solid Tumors PHASE1COMPLETED
BTK Inhibitor DTRMWXHS-12 in Mantle Cell Lymphoma PHASE1COMPLETED
A Study of IMMH-010 in Patients With Advanced Malignant Solid Tumors PHASE1UNKNOWN
A Randomized, Double-blind, Study to Explore the Effect of GED-0301 in Subjects With Active Crohn's Disease PHASE1COMPLETED
Study of 68Ga-R10602 PHASE1RECRUITING
Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Transplant PHASE1COMPLETED
BGT007H Cells for the Treatment of Refractory Digestive System Tumors EARLY_PHASE1RECRUITING
Clinical Study of MRD Recurrence Monitoring After Surgical Resection of Hepatocellular Carcinoma nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a GGH binder may also engage these)

ProteinNameSimilarity
A7YWG4 — 0.995 A7YWG4 →
Q62867 — 0.994 Q62867 →
Q9Z0L8 — 0.990 Q9Z0L8 →
O65355 — 0.982 O65355 →
Q9SYL6 — 0.981 Q9SYL6 →
Q9ZV85 — 0.980 Q9ZV85 →
P93164 — 0.974 P93164 →
Q05A56 — 0.973 Q05A56 →
Q2M3T9 — 0.972 Q2M3T9 →
P29416 — 0.971 P29416 →
Q9D3S9 — 0.971 Q9D3S9 →
Q5RFD6 — 0.970 Q5RFD6 →
P14384 — 0.970 P14384 →
Q9H3G5 — 0.970 Q9H3G5 →
Q641X3 — 0.969 Q641X3 →
Q0P5B7 — 0.969 Q0P5B7 →
Q2KIM0 — 0.969 Q2KIM0 →
O95498 — 0.969 O95498 →
P31428 — 0.968 P31428 →
O55070 — 0.968 O55070 →
Q80V42 — 0.968 Q80V42 →
Q4QR71 — 0.968 Q4QR71 →
Q9CQF9 — 0.968 Q9CQF9 →
O70410 — 0.967 O70410 →
Q6AXR4 — 0.967 Q6AXR4 →
HEXA Beta-hexosaminidase subunit alpha 0.967 landscape →
Q8WXQ8 — 0.967 Q8WXQ8 →
Q29444 — 0.967 Q29444 →
Q8K2I4 — 0.967 Q8K2I4 →
FUCA2 Plasma alpha-L-fucosidase 0.967 landscape →